Vandetanib

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

Selpercatinib appeared to be effective and safe for patients with RET-altered medullary thyroid cancer and RET fusion-positive non-small cell lung cancer, according to results of two studies published in The New England Journal of Medicine.

Vandetanib extended PFS among patients with symptomatic and progressive medullary thyroid cancer, according to results of a post hoc analysis of a randomized phase 3 study published in Journal of Clinical Oncology.